Related Experiment Video

Updated: Aug 6, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy

I Jedema1, R M Y Barge, V H J van der Velden

  • 1Laboratory of Experimental Hematology, Department of Hematology, Leiden University Medical Center, The Netherlands. i.jedema@lumc.nl

Leukemia
|November 14, 2003
PubMed

Insights

Gemtuzumab Ozogamicin (GO) shows efficacy in acute myeloid leukemia by partially CD33-mediated cell death and also through endocytosis in CD33-negative cells. Leukemia cell activation status influences GO sensitivity.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Gemtuzumab Ozogamicin (GO) is an antibody-drug conjugate targeting CD33, used in relapsed acute myeloid leukemia (AML).
  • Previous trials showed a 30% response rate but lacked clear correlation between CD33 expression and GO efficacy.
  • The precise mechanisms of GO action, especially in CD33-negative settings, require further elucidation.

Purpose of the Study:

  • To investigate the CD33 specificity of GO-induced cytotoxicity.
  • To explore the efficacy of GO in CD33-negative malignancies.
  • To identify factors influencing sensitivity to GO therapy.

Main Methods:

  • Analysis of GO-induced cell death in relation to CD33 expression.
  • In vitro and in vivo studies using CD33-negative acute lymphoblastic leukemia (ALL) cells in an NOD/SCID mouse model.
  • Assessment of leukemic cell activation status and its impact on GO internalization and cell death.

Main Results:

  • GO-induced cell lysis is partially CD33-mediated.
  • Efficient non-CD33-mediated GO uptake occurs via endocytosis.
  • GO demonstrated efficacy against CD33-negative ALL cells in vitro and in vivo.
  • Leukemic cell cycle activation status significantly impacts GO sensitivity and uptake.

Conclusions:

  • GO exhibits efficacy beyond CD33 expression, involving endocytic mechanisms.
  • The findings support the use of GO in CD33-negative malignancies with endocytic capacity.
  • Leukemic cell activation status is a critical determinant of GO response, offering potential therapeutic insights.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...